Displaying 174 (all) recruiting clinical trials.
-
A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations
If you have been diagnosed with intermediate or high risk Myelodysplastic Syndrome with a mutation in the Tet methylcytosine dioxygenase (abbreviated as TET) gene, you ... -
APEC1621SC: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
If you or your child have cancer that has become worse following treatment, or because no standard therapy exists for your type of cancer, you ... -
NMTRC14: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
If you or your child have been diagnosed with neuroblastoma that is now in remission, you or your child may be qualified to participate in ... -
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
If you or your child has been diagnosed with high grade gliomas (a type of brain cancer), you or your child may qualify to participate ... -
Paroxysmal nocturnal hemoglobinuria (PNH) Registry
This is a non interventional registry to gather information on the clinical presentation and outcomes of patients with PNH. The PHN Registry will capture post-marketing ... -
Colorectal Cancer Metastatic MSI-High Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Micros
If you have been diagnosed with Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer, you may qualify for this Phase 3 study. The main goal of this ... -
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
If you have been diagnosed with colon cancer that was surgically removed but has spread to lymph nodes and is known as stage III colon ... -
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
If you have been diagnosed with a rare cancer or a rare cancer of unknown primary origin, you may qualify for this study. The main ... -
CDA Diefenbach Medpace Protocol ID ME-522-001 titled: A Phase 1 Open-label Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies
If you have been diagnosed with a B cell type cancer that has relapsed (come back) or is refractory (did not respond to previous treatment ... -
A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer
If you have been diagnosed with advanced, metastatic, non-small cell lung cancer (NSCLC), you may qualify for this study. The main goal of this study ...